Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension

Blood Pressure Monitoring

Volumn 19, Issue 2, 2014, Pages 90-97

  Weber, Michael A ^a   White, William B ^b   Sica, Domenic ^c   Bakris, George L ^d   Cao, Charlie ^e   Roberts, Andrew ^e   Kupfer, Stuart ^f  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

^f Takeda Pharmaceuticals International   (United States)

Author keywords

Ambulatory blood pressure monitoring; Amlodipine; Angiotensin II receptor blockers; Azilsartan medoxomil

Indexed keywords

AMLODIPINE; AZILSARTAN MEDOXOMIL; CREATININE; PLACEBO; POTASSIUM; URIC ACID;

ADULT; AMBULATORY MONITORING; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; EDEMA; FAINTNESS; FEMALE; FLUID RETENTION; GOUT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; POSITIONAL DIZZINESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

AGED; AMLODIPINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OXADIAZOLES;

EID: 84897075784     PISSN: 13595237     EISSN: 14735725     Source Type: Journal    
DOI: 10.1097/MBP.0000000000000027     Document Type: Article

References (32)

1. Russell D, Stalhammar J, Bodegard J, Hasvold P, Thuresson M, Kjeldsen SE. Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan. J Clin Hypertens (Greenwich) 2011; 13: 189-197.
2. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
3. Roy J, Shah NR, Wood GC, Townsend R, Hennessey S. Comparative effectiveness of angiotensin converting enzyme inhibitors and angiotensin receptor blockers for hypertension on clinical end points: a cohort study. J Clin Hypertens (Greenwich) 2012; 14: 407-414.
4. Kjeldsen SE, Stalhammar J, Hasvold P, Bodegard J, Olsson U, Russell D. Effects of losartan vs candasartan in reducing cardiovascular events in the primary treatment of hypertension. J Hum Hypertens 2010; 24: 263-273.
5. Wells T, Blumer J, Meyers KEC, Neto JPR, Meneses R, Litwin M, et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) 2011; 13: 357-365.
6. Izzo JL, Weintraub HS, Duprez DA, Purkayastha D, Zappe D, Samuel R, Cushman WC. Treating systolic hypertension in the very elderly with valsartan-hydrochlorothiazide vs either monotherapy: ValVET primary results. J Clin Hypertens (Greenwich) 2011; 13: 722-730.
7. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
8. Frishman WH, Ram CV, McMahon FG, Chrysant SG, Graff A, Kupiec JW, Hsu H. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol 1995; 35: 1060-1066.
9. Ram CV. Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies. Curr Med Res Opin 2009; 25: 177-185.
10. Weir MR, Hsueh W, Nesbitt SD, Littlejohn TJ, Graff A, Shojaee A, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed dose combinations of amlodipine and olmesartan medoxomil. J Clin Hypertens (Greenwich) 2011; 13: 404-412.
11. Punzi H, Shojaee A, Waverczak WF, Maa JF. Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity. J Clin Hypertens (Greenwich) 2011; 13: 422-430.
12. Neutel JM, Mancia G, Black HR, Dahlof B, Defeo H, Ley L, Vinisko R. TEAMSTA Severe HTN Study Investigators. Single pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. J Clin Hypertens (Greenwich) 2012; 14: 206-215.
13. Lüscher TF, Wenzel RR, Moreau P, Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995; 9 (Suppl 3): 509-523.
14. Neutel JM, Smith DH, Weber MA. Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens 2004; 17: 37-42.
15. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.
16. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V. On behalf of the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
17. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ 2011; 343:d4891.
18. Takeda Pharmaceuticals America Inc. Edarbi (azilsartan medoxomil) package insert. Deerfield, IL: Takeda Pharmaceuticals America Inc.; 2011.
19. White WB, Weber MA, Sica D, Bakris GL, Perez A, Cao C, Kupfer S. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011; 57: 413-420.
20. Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011; 13: 81-88.
21. Ram CVS, Ramaswamy K, Qian C, Biskupiak J, Ryan A, Quah R, Russo PA. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data. J Clin Hypertens (Greenwich) 2011; 13: 801-812.
22. Ram CVS, Vasey J, Panjabi S, Qian C, Quah R. Comparative effectiveness analysis of amlodipine/renin angiotensin system blocker combinations. J Clin Hypertens (Greenwich) 2012; 14: 601-610.
23. Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011; 13: 467-472.
24. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension 2012; 60: 310-318.
25. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997
27. Errata in JAMA 2004; 291: 2196
28. 2003; 289:178.
29. Sica D, Bakris L, White WB, Weber MA, Cushman WC, Huang P, et al. Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study. J Clin Hypertens (Greenwich) 2012; 14: 284-292.
30. Izzo JL, Chrysant SG, Kereiakes DJ, Littlejohn T, Oparil S, Melino M, et al. 24-hour efficacy and safety of triple-combination therapy with olmesartan, amlodipine and hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. J Clin Hypertens (Greenwich) 2011; 13: 873-880.
31. Kereiakes DJ, Chrysant SG, Izzo JL, Littlejohn T, Oparil S, Melino M, et al. Long-term efficacy and safety of triple combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension. J Clin Hypertens (Greenwich) 2012; 14: 149-157.
32. Allemann Y, Fraile B, Lambert M, Barbier M, Ferber P, Izzo JL. Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study. J Clin Hypertens (Greenwich) 2008; 10: 185-194.